Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia

Pediatric Infectious Disease Journal

Volumn 33, Issue SUPPL. 2, 2014, Pages

  Loo, Jennifer D ^a   Conklin, Laura ^a   Fleming Dutra, Katherine E ^a,b   Knoll, Maria Deloria ^c   Park, Daniel E ^c   Kirk, Jennifer ^d   Goldblatt, David ^e   O'Brien, Katherine L ^c   Whitney, Cynthia G ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WESTAT   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunization schedule; Pneumococcal conjugate vaccine; Pneumonia; Systematic review

Indexed keywords

PNEUMOCOCCUS VACCINE;

ASIA; AUSTRALIA; DRUG EFFICACY; EMPYEMA; EUROPE; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW;

CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; OBSERVATIONAL STUDY AS TOPIC; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, CONJUGATE;

EID: 84891375096     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000082     Document Type: Review

References (64)

1. O'Brien KL, Wolfson LJ, Watt JP, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age. 2008. Available at: http://www.who.int/ immunization-monitoring/burden/Pneumo-hib-estimates/en/index.html. Accessed March 18, 2013.
3. L ucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev. 2004:CD004977.
4. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec. 2007;12: 93-104.
5. World Health Organization and UNICEF. Global Action Plan for Prevention and Control of Pneumonia (GAPP). 2009. Available at: http://whqlibdoc. who.int/hq/2009/WHO-FCH-CAH-NCH-09.04-eng.pdf. Accessed March 18, 2013.
6. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.
7. E uropean Medicines Agency. Prevenar. 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000323/human-med-000987.jsp&jsenabled=true. Accessed March 12, 2012.
8. E uropean Medicines Agency. Prevenar 13. 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001104/human-med-001220.jsp&mid=WC0b01ac058001d124. Accessed October 16, 2013.
9. E uropean Medicines Agency. Synflorix. 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000973/human-med-001071.jsp&mid=WC0b01ac058001d124. Accessed March 12, 2012.
10. IVAC, Johns Hopkins Bloomberg School of Public Health. Vaccine Information Management System (VIMS) Global Vaccine Introduction Report. March, 2013. Available at: www.jhsph.edu/ivac/vims.html. Accessed April 15, 2013.
11. Conklin L, Loo JD, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33 (Suppl 2):S109-S118.
12. Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33 (Suppl 2):S152-S160.
13. Deloria Knoll M, Park D, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33 (Suppl 2):S119-S129.
14. Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33 (Suppl 2):S161-S171.
15. Loo JD, Conklin L, Deloria Knoll M, et al. Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. Pediatr Infect Dis J. 2014;33 (Suppl 2):S182-S187.
16. Hanquet G, Lernout T, Vergison A, et al.; Belgian IPD Scientific Committee. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29:2856-2864.
17. Moore M, Pilishvili T, Farley M, et al. Trends in invasive pneumococcal pneumonia, selected US sites, 1998-2006. 6th International Symposium on Pneumococci and Pneumococcal Disease; June 8-12, 2008. Reykjavik, Iceland. Abstract 371.
18. Richmond P, Phuanukoonnon S, Jacoby P, et al. Effect of neonatal and early immunisation with heptavalent pneumococcal conjugate vaccine on morbidity and pneumonia in Papua New Guinea. 6th International Symposium on Pneumococci and Pneumococcal Disease; June 8-12, 2008. Reykjavik, Iceland. Abstract 345.
19. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309-e00310.
20. Singleton R, Holman R, Yorita K, et al. Pneumococcal empyema and pleural effusion among Alaska Native children less than 10 yrs of age. 6th International Symposium on Pneumococci and Pneumococcal Disease; June 8-12, 2008. Reykjavik, Iceland. Abstract 87.
21. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161:1162-1168.
22. Klugman KP, Madhi SA, Huebner RE, et al.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
23. Cutts FT, Zaman SM, Enwere G, et al.; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-1146.
24. Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics. 2004;113:1735-1740.
25. L ucero MG, Nohynek H, Williams G, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J. 2009;28:455-462.
26. M adhi SA, Kuwanda L, Cutland C, et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis. 2005;40:1511-1518.
27. Balazs GC, Garcia FJ, Yamamoto LG. Conjugate heptavalent pneumococcal vaccine outcome improvements. Hawaii Med J. 2006;65:288-289.
28. P elton SI, Weycker D, Klein JO, et al. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine. 2010;28:1575-1582.
29. Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine. 2008;26:5944-5951.
30. Ansaldi F, Sticchi L, Durando P, et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J Int Med Res. 2008;36:1255-1260.
31. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
32. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.Pediatr Infect Dis J. 2006;25:250-254.
33. Calbo E, Díaz A, Cañadell E, et al.; Spanish Pneumococcal Infection Study Network. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12:867-872.
34. De Wals P, Robin E, Fortin E, et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2008;27:963-968.
35. E sposito S, Lizioli A, Lastrico A, et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir Res. 2007;8:12.
36. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118:865-873.
37. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
38. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
39. Hendrickson DJ, Blumberg DA, Joad JP, et al. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27:1030-1032.
40. Rutman MS, Bachur R, Harper MB. Radiographic pneumonia in young, highly febrile children with leukocytosis before and after universal conjugate pneumococcal vaccination. Pediatr Emerg Care. 2009;25:1-7.
41. Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate pneumococcal vaccine in Arkansas. Pediatr Infect Dis J. 2004;23:1125-1129.
42. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J. 2005;24:10-16.
43. N elson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947-4954.
44. M uñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182.
45. Roche PW, Krause V, Cook H, et al.; Enhanced Invasive Pneumococcal Disease Surveillance Working Group; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep. 2008;32:18-30.
46. Kaplan SL, Mason EO Jr., Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 pt 1):443-449.
47. Aristegui J, Bernaola E, Pocheville I, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26:303-310.
48. Grijalva CG, Nuorti JP, Zhu Y, et al. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010;50:805-813.
49. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010;29:607-612.
50. Koshy E, Murray J, Bottle A, et al. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax. 2010;65:770-774.
51. L i ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125:26-33.
52. O'Grady KF, Carlin JB, Chang AB, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against radiologically diagnosed pneumonia in indigenous infants in Australia. Bull World Health Organ. 2010;88:139-146.
53. O'Grady KA, Lee KJ, Carlin JB, et al. Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: a cohort study. Clin Infect Dis. 2010;50:970-978.
54. P atrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2010;29:787-792.
55. T wele L, Haider S, Nettel-Aguirre A, et al. Has the 7-valent pneumococcal conjugate vaccine (PCV7) reduced hospital visits and admissions for pneumonia in young children in Calgary? Int J Antimicrob Agents. 2009;34:S5-S6.
56. O'Brien KL. The effect of conjugate pneumococcal vaccine on pneumonia and otitis media among Navajo and White Mountain Apache children. 3rd International Symposium on Pneumococci and Pneumcooccal Disease; May 5-8, 2002, Anchorage, AK.
57. T regnaghi MW, Sáez-Llorens X,López P, et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-d conjugate vaccine (PHID-CV) against community-acquired pneumonia in Latin America. European Society of Pediatric Infectious Disease; June 7-11, 2011. The Hague, Netherlands.
58. Scott P, Rutjes AW, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine. 2011;29:9711-9721.
59. Cheung YB, Zaman SM, Ruopuro ML, et al. C-reactive protein and procalcitonin in the evaluation of the efficacy of a pneumococcal conjugate vaccine in Gambian children. Trop Med Int Health. 2008;13:603-611.
60. M adhi SA, Kohler M, Kuwanda L, et al. Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J. 2006;25:30-36.
61. Cohen C, von Mollendorf C, Naidoo N, et al. South African IPD Case-Control Study Group. Effectiveness of seven-valent pneumococcal conjugate vaccine (PCV7) against invasive pneumococcal disease in South Africa: a matched case-control study. 8th International Symposium on Pneumococci and Pneumococcal Disease; March 11-15, 2012, Igacu Falls, Brazil.
62. M adhi SA, Groome M, Zar H, et al. Effectiveness of pneumococcal conjugate vaccine (PCV) against presumed bacterial pneumonia (PBP) in South African HIV-uninfected children: a case-control study. 8th International Symposium on Pneumococci and Pneumococcal Disease; March 11-15, 2012, Igacu Falls, Brazil. Abstract 8.
63. P an American Health Organization. Technical Advisory Group on Vaccine-Preventable Diseases. Final Report; July 6-8, 2011, Buenos Aires, Argentina.
64. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011 -conclusions and recommendations. Wkly Epidemiol Rec. 2012:1-16.